Zura Bio (ZURA) Expected to Announce Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Zura Bio to post earnings of ($0.17) per share for the quarter.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter. On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Performance

Shares of ZURA traded down $0.16 during mid-day trading on Tuesday, hitting $1.29. The company's stock had a trading volume of 87,188 shares, compared to its average volume of 386,634. The firm has a market capitalization of $87.86 million, a PE ratio of -2.42 and a beta of 0.05. The stock's 50-day moving average is $1.28 and its two-hundred day moving average is $2.17. Zura Bio has a one year low of $0.97 and a one year high of $6.35.

Hedge Funds Weigh In On Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE lifted its holdings in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 41,222 shares of the company's stock after purchasing an additional 9,966 shares during the period. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 at the end of the most recent reporting period. 61.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Guggenheim reissued a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a research note on Thursday, April 3rd. Finally, Oppenheimer restated an "outperform" rating and issued a $19.00 price objective (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.